These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25457851)

  • 61. Reply: To PMID 25917786.
    Brandse JF; D'Haens GR
    Gastroenterology; 2015 Dec; 149(7):1989-90. PubMed ID: 26515491
    [No Abstract]   [Full Text] [Related]  

  • 62. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Onset of ulcerative colitis under treatment with adalimumab.
    Tursi A; Penna A
    Am J Gastroenterol; 2008 Sep; 103(9):2410-2. PubMed ID: 18844636
    [No Abstract]   [Full Text] [Related]  

  • 64. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
    Luthra P; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1227-36. PubMed ID: 25903741
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
    Gies N; Kroeker KI; Wong K; Fedorak RN
    Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fecal Infliximab Loss.
    Gibson DJ; Doherty GA
    Gastroenterology; 2015 Dec; 149(7):1989. PubMed ID: 26515485
    [No Abstract]   [Full Text] [Related]  

  • 68. Letter: infliximab in severe ulcerative colitis - is it useful for all patients?
    Barreiro-de Acosta M; Gisbert JP
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1413. PubMed ID: 24206379
    [No Abstract]   [Full Text] [Related]  

  • 69. [Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis].
    Ainsworth MA; Brynskov J
    Ugeskr Laeger; 2007 Feb; 169(9):789-91. PubMed ID: 17355841
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Moss AC; Farrell RJ
    Gastroenterology; 2006 Nov; 131(5):1649-51; discussion 1651. PubMed ID: 17067595
    [No Abstract]   [Full Text] [Related]  

  • 71. [Bio-target therapy for refractory ulcerative colitis].
    Li SR
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3099-101. PubMed ID: 19159588
    [No Abstract]   [Full Text] [Related]  

  • 72. Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy.
    Tursi A; Della Valle N; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Aliment Pharmacol Ther; 2016 Mar; 43(5):657-8. PubMed ID: 26843348
    [No Abstract]   [Full Text] [Related]  

  • 73. Ulcerative Colitis: Update on Medical Management.
    Iskandar HN; Dhere T; Farraye FA
    Curr Gastroenterol Rep; 2015 Nov; 17(11):44. PubMed ID: 26386686
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis.
    Patel B; Butterfield JH; Weiler CR; Kane SV
    Monoclon Antib Immunodiagn Immunother; 2016 Dec; 35(6):300-303. PubMed ID: 27911676
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Therapy of ulcerative colitis].
    Vavricka SR; Rogler G
    Praxis (Bern 1994); 2009 Feb; 98(4):209-12. PubMed ID: 19224489
    [TBL] [Abstract][Full Text] [Related]  

  • 76. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.
    Zacharias P; Damião AOMC; Moraes AC; Teixeira FV; Ludvig JC; Nones RB; Saad-Hossne R; Sassaki LY; Silva RPLD; Facchin L; Olandoski M; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):321-327. PubMed ID: 28977114
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Infliximab in refractory severe ulcerative colitis: a case report.
    Bossa F; Caserta L; Selvaggi F; Riegler G
    Minerva Gastroenterol Dietol; 2005 Sep; 51(3):261-2. PubMed ID: 16280968
    [No Abstract]   [Full Text] [Related]  

  • 78. Letter: infliximab in severe ulcerative colitis - is it useful for all patients? Authors' reply.
    Sjöberg M; Halfvarson J; Tysk C
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1413-4. PubMed ID: 24206380
    [No Abstract]   [Full Text] [Related]  

  • 79. Subcutaneous golimumab therapy for ulcerative colitis.
    Lowe AW; Moseley RH
    Gastroenterology; 2014 Jan; 146(1):1-2. PubMed ID: 24501748
    [No Abstract]   [Full Text] [Related]  

  • 80. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
    Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
    Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.